- Home
- / Intellia Therapeutics
Intellia Therapeutics
Stock Price
$16.3
2024-10-28
Market Capitalization
$1.7 B
2024-10-28
Revenue
$67.7 M
FY, 2025
Intellia Therapeutics Summary
Company Summary
- Overview
- Intellia Therapeutics is a genome editing company that caters to the biotechnology industry. It focuses mainly on CRISPR-based research, creates cell therapies for various cancers and autoimmune diseases, and develops treatments for patients with chronic diseases.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.intelliatx.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Eliana Clark, Executive Vice President, Chief Technical Officer
David Lebwohl, Executive Vice President, Chief Medical Officer
Fred Cohen, Independent Director
LocationsView all
1 location detected
Cambridge, MA HQ
United States
40 Erie St #130
Intellia Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $15.0M
- Net income (Q1, 2026)
- ($96.2M)
- Cash (Q1, 2026)
- $134.7M
- EBIT (Q1, 2026)
- ($100.5M)
- Enterprise value
- $1.6B